Intra-Cellular Therapies Inc.

57.73-0.7700-1.32%Vol 873.27K1Y Perf 53.62%
May 19th, 2022 16:00 DELAYED
BID57.00 ASK60.66
Open58.75 Previous Close58.50
Pre-Market- After-Market57.73
 - -  - -%
Target Price
66.75 
Analyst Rating
Strong Buy 1.50
Potential %
15.62 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     54.64
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
78.01 
Earnings Rating
Neutral
Market Cap5.45B 
Earnings Date
10th May 2022
Alpha0.05 Standard Deviation0.37
Beta1.27 

Today's Price Range

57.3960.64

52W Range

28.4066.00

5 Year PE Ratio Range

-8.80-8.50

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-2.32%
1 Month
-3.83%
3 Months
1.94%
6 Months
43.32%
1 Year
53.62%
3 Years
369.73%
5 Years
440.04%
10 Years
-

TickerPriceChg.Chg.%
ITCI57.73-0.7700-1.32
AAPL137.35-3.4700-2.46
GOOG2 214.91-33.1100-1.47
MSFT253.14-0.9400-0.37
XOM91.140.49000.54
WFC42.00-0.1100-0.26
JNJ173.94-1.5600-0.89
FB191.29-0.9500-0.49
GE75.740.54000.72
JPM118.31-1.7800-1.48
Financial StrengthValueIndustryS&P 500US Markets
13.60
14.40
0.02
0.03
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
90.40
-302.50
-301.90
-
-
RevenueValueIndustryS&P 500US Markets
100.88M
1.07
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.93-0.7816.13
Q04 2021-1.05-1.050.00
Q03 2021-0.89-0.95-6.74
Q02 2021-0.79-0.85-7.59
Q01 2021-0.81-0.6519.75
Q04 2020-0.85-0.7610.59
Q03 2020-0.96-0.7917.71
Q02 2020-0.94-0.96-2.13
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.80-2.56Negative
9/2022 QR-0.75-7.14Negative
12/2022 FY-2.98-2.05Negative
12/2023 FY-1.2418.42Positive
Next Report Date-
Estimated EPS Next Report-0.93
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume873.27K
Shares Outstanding94.32K
Shares Float81.96M
Trades Count16.83K
Dollar Volume51.09M
Avg. Volume949.16K
Avg. Weekly Volume905.36K
Avg. Monthly Volume998.83K
Avg. Quarterly Volume943.29K

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) stock closed at 57.73 per share at the end of the most recent trading day (a -1.32% change compared to the prior day closing price) with a volume of 873.27K shares and market capitalization of 5.45B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 383 people. Intra-Cellular Therapies Inc. CEO is Sharon Mates.

The one-year performance of Intra-Cellular Therapies Inc. stock is 53.62%, while year-to-date (YTD) performance is 10.3%. ITCI stock has a five-year performance of 440.04%. Its 52-week range is between 28.4 and 66, which gives ITCI stock a 52-week price range ratio of 78.01%

Intra-Cellular Therapies Inc. currently has a PE ratio of -16.20, a price-to-book (PB) ratio of 7.03, a price-to-sale (PS) ratio of 55.09, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.32%, a ROC of -41.78% and a ROE of -44.28%. The company’s profit margin is -%, its EBITDA margin is -301.90%, and its revenue ttm is $100.88 Million , which makes it $1.07 revenue per share.

Of the last four earnings reports from Intra-Cellular Therapies Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.93 for the next earnings report. Intra-Cellular Therapies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Intra-Cellular Therapies Inc. is Strong Buy (1.5), with a target price of $66.75, which is +15.62% compared to the current price. The earnings rating for Intra-Cellular Therapies Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intra-Cellular Therapies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intra-Cellular Therapies Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 16.56, ATR14 : 3.31, CCI20 : 112.37, Chaikin Money Flow : -0.04, MACD : 0.01, Money Flow Index : 61.79, ROC : 13.00, RSI : 56.45, STOCH (14,3) : 91.16, STOCH RSI : 0.80, UO : 64.98, Williams %R : -8.84), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intra-Cellular Therapies Inc. in the last 12-months were: Christopher Alafi (Sold 75 000 shares of value $3 017 236 ), Joel S. Marcus (Option Excercise at a value of $0), Joel S. Marcus (Sold 20 000 shares of value $1 062 750 ), Lawrence J. Hineline (Option Excercise at a value of $2 941 950), Lawrence J. Hineline (Sold 205 082 shares of value $9 707 589 ), Mark Neumann (Option Excercise at a value of $1 099 210), Mark Neumann (Sold 131 883 shares of value $7 577 683 ), Michael I. Halstead (Option Excercise at a value of $2 897 493), Michael I. Halstead (Sold 207 641 shares of value $9 830 151 ), Rory B. Riggs (Option Excercise at a value of $0), Sharon Mates (Option Excercise at a value of $142 000), Sharon Mates (Sold 119 743 shares of value $5 250 841 ), Suresh K. Durgam (Option Excercise at a value of $0), Suresh K. Durgam (Sold 25 307 shares of value $1 224 844 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (62.50 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
2 (25.00 %)
2 (28.57 %)
2 (28.57 %)
Hold
1 (12.50 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.29
Strong Buy
1.29

Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

CEO: Sharon Mates

Telephone: +1 646 440-9333

Address: 430 East 29th Street, New York 10016, , US

Number of employees: 383

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

39%61%

Bearish Bullish

50%50%

TipRanks News for ITCI

News

Stocktwits